Survival Rate Of Treatment Group Research Articles

Shenfu injection provides protection for perinatal asphyxia in neonates

<p class="Abstract">This study aimed to investigate the efficacy of shenfu injection for the protection of neonates with asphyxia. Eighty neonates with asphyxia were randomly divided into two groups, treatment group and control group (n=40). Both groups received interventions such as ventilation, oxygen, and circulation support. Treatment group was administrated with shenfu injection additionally. Serum levels of creatine kinase, alanine aminotransferase, aspartate aminotransferase, creatinine, and neuron-specific enolase were significantly lower but the oxygenation index was significantly higher in treatment group on day 7 and day 14. The neurobehavioral score was significantly higher in treatment group than in control group. On the 14<sup>th</sup> day, the survival rate of treatment group (77.5%) was higher than that of control group (55%). Shenfu injection could protect the function of the brain, heart, lung, liver and kidney by attenuating ischemia reperfusion after severe asphyxia resuscitation, improve neurobehavioral ability and increase the survival of neonates.</p><p> </p>

Covariate-adjusted non-parametric survival curve estimation

Kaplan-Meier survival curve estimation is a commonly used non-parametric method to evaluate survival distributions for groups of patients in the clinical trial setting. However, this method does not permit covariate adjustment which may reduce bias and increase precision. The Cox proportional hazards model is a commonly used semi-parametric method for conducting adjusted inferences and may be used to estimate covariate-adjusted survival curves. However, this model relies on the proportional hazards assumption that is often difficult to validate. Research work has been carried out to introduce a non-parametric covariate-adjusted method to estimate survival rates for certain given time intervals. We extend the non-parametric covariate-adjusted method to develop a new model to estimate the survival rates for treatment groups at any time point when an event occurs. Simulation studies are conducted to investigate the model's performance. This model is illustrated with an oncology clinical trial example.

A prospective, randomized, controlled, multicenter trial of Chinese herbs by stages combined with chemotherapy for advanced non-small cell lung cancer.

e18000 Background: Chemotherapy plays an important role in the treatment of advanced non-small cell lung cancer (NSCLC), but the overall survival (OS) and the median survival time (MST) are not satisfactory. Chinese herbs (CH) is a popular treatment for NSCLC in china. Our purpose was to observe the efficacy of CH by stages combined with chemotherapy versus chemotherapy alone for NSCLC (stage III/IV). Methods: A prospective, randomized, controlled, multicenter, clinical trial was conducted on 115 patients assigned to treatment group (60) and control group (55). The control group was treated by chemotherapy (cisplatin and gemcitabine [GP]/cisplatin and vinorelbine [NP]) alone, while the treatment group was treated by chemotherapy (GP/NP) combined with CH and was administered Kangliuzengxiao decoction (KLZX) during chemotherapy course and Feiyanning decoction (FYN) maintenance after chemotherapy. End points were OS, MST, response rate, toxicity, and Karnofsky score. Results: MST was 14.47 months (95% confidence interval, 10.37 to 18.57) in treatment group compared with 10.97 months (95% confidence interval, 9.35 to 12.59) in control group (p = 0.001). 1 year, 2 years, 3 years, 5 years survival rates in treatment group were 54.8%, 24.6%, 13.2%, 5.7%, compared to control group 35.6%, 3.7%, 0%, 0% (p = 0.001). The response rates (CR+PR) were 28.3% (treatment group) and 18.2% (control group), there was no statistically significant difference in response rate between the two groups. The toxicities mainly were gastrointestinal dysfunction and myelosuppression of different degrees. Remission rate of nausea/vomiting symptoms was high after patients treated with CH in treatment group (p < 0.05), myelosuppression was more significant in control group than in treatment group (p < 0.05). Karnofsky score of treatment group was higher than that of control group (p < 0.01) (p < 0.01). Conclusions: In this trial, chinese herbs by stages combined with chemotherapy could prolong the MST and OS,still improve Karnofsky score, while the toxicity was not enhanced. Chinese herbal medicine was a promising maintenance treatment for advanced NSCLC. No significant financial relationships to disclose.

Expression of phosphatase and tensin homolog deleted on chromosome ten in liver of athymic mice with hepatocellular carcinoma and the effect of Fuzheng Jiedu Decoction

To explore the expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in liver of athymic mice with hepatocellular carcinoma (HCC) and the effect of Fuzheng Jiedu Decoction (FJD). Forty eight male BALB/c athymic mice models were built by Bel-7402 with an indirect method. After 24 h of postoperation, the 48 athymic mice were distributed randomly into 4 groups: A, B, C, D, each group had 12 athymic mice. Group A were were treated by intragastric administration with FT207 (Tegafur) for 4 wk. Group B, C and D were treated by intragastric administration with FJD (complex prescription of Chinese crude drug) that had been delegated into 3 kinds of density as the low, middle, and high for 4 wk. At last, athymic mice were put to death, live time, volume of tumors, exponent of tumors and the tumor metastasis in livers were observed; and PTEN was detected in hepatic tissue, latero-cancer tissue and cancer tissue by immunohistochemistry. Four weeks later, the total survival rate in treatment group (A + B + C) was 50% and higher than the control group (0%) treated by FT207, (P < 0.01). The survival rate in group A, B, C was higher than in group D, and except group A with D, there was significant differences (Fisher's Exact Test P = 0.05 or 0.01). And no differences were observed between the treatment groups and the control group in volume of tumors and exponent of tumors (P > 0.05). Tumor metastasis in livers of the treatment group was less than the controls (Fisher's Exact Test, P = 0.021). The result of immunohistochemistry showed that the intensity of PTEN in latero-cancer tissue was the highest, and then the hepatic tissue, the lowest was cancer tissue (Kruskal-Wallis test, chi2 = 60.67, P = 0.000). It also showed that the intensity of PTEN in treatment groups (A, B, C) was higher than the control group (D) (F = 5.90, P = 0.002 in hepatic tissue and F = 15.99, P = 0.000 in latero-cancer tissue and chi2 = 26.08, P = 0.000 in cancer tissue), and group B is the highest in the treatment groups (P < 0.05, r = 0.01. respectively). However, there was no significant statistic difference between group A and group C (P > 0.05). FJD can prolong the survival time and decrease tumor metastasis in livers of these experimental mice. Mechanisms of FJD healing HCC may partially be explained by enhancing the expression of PTEN in liver.

Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy.

Between 1970 and 1982, 175 patients with Stage IA, B, IIA, B, or IIIA Hodgkin's disease were treated with curative radiotherapy following surgical staging. The patients treated prior to 1975 received either regular extended or total nodal field treatments (Treatment Group 1, N = 65). Unsatisfactory results from this treatment program led to treatment modification in 1975. The modified protocols consisted of low-dose lung irradiation in patients having large mediastinal masses and/or hilar disease, and low-dose liver irradiation for Stage IIIAS+ patients (Treatment Group 2, N = 110). Recurrence-free survival rates improved significantly for various risk groups. Univariate analysis indicated that age, stage, symptoms, mediastinal mass size, number of sites involved, hilar disease, stage, and symptoms were significant risk factors in Treatment Group 1. In Treatment Group 2, only sex was a statistically significant risk factor. Stepwise Cox regression analysis for risk factors selected mediastinal mass size and stage as the most significant prognostic factors in Treatment Group 1. In Treatment Group 2, number of initial disease sites and sex were the most significant risk factors. The results of the study show significant improvement in recurrence-free survival rates in Treatment Group 2. It is concluded that these improvements are due to the modification in treatment.